JP2013136631A5 - - Google Patents

Download PDF

Info

Publication number
JP2013136631A5
JP2013136631A5 JP2013055494A JP2013055494A JP2013136631A5 JP 2013136631 A5 JP2013136631 A5 JP 2013136631A5 JP 2013055494 A JP2013055494 A JP 2013055494A JP 2013055494 A JP2013055494 A JP 2013055494A JP 2013136631 A5 JP2013136631 A5 JP 2013136631A5
Authority
JP
Japan
Prior art keywords
formula
alkyl
aryl
compound
deoxorapamycin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2013055494A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013136631A (ja
Filing date
Publication date
Priority claimed from GBGB0601406.2A external-priority patent/GB0601406D0/en
Application filed filed Critical
Publication of JP2013136631A publication Critical patent/JP2013136631A/ja
Publication of JP2013136631A5 publication Critical patent/JP2013136631A5/ja
Pending legal-status Critical Current

Links

JP2013055494A 2006-01-24 2013-03-18 ラパマイシン誘導体の製造方法 Pending JP2013136631A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0601406.2 2006-01-24
GBGB0601406.2A GB0601406D0 (en) 2006-01-24 2006-01-24 Organic Compounds

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2008551707A Division JP5416412B2 (ja) 2006-01-24 2007-01-22 ラパマイシン誘導体の製造方法

Publications (2)

Publication Number Publication Date
JP2013136631A JP2013136631A (ja) 2013-07-11
JP2013136631A5 true JP2013136631A5 (enExample) 2013-10-03

Family

ID=36060760

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2008551707A Expired - Fee Related JP5416412B2 (ja) 2006-01-24 2007-01-22 ラパマイシン誘導体の製造方法
JP2013055494A Pending JP2013136631A (ja) 2006-01-24 2013-03-18 ラパマイシン誘導体の製造方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2008551707A Expired - Fee Related JP5416412B2 (ja) 2006-01-24 2007-01-22 ラパマイシン誘導体の製造方法

Country Status (11)

Country Link
US (1) US8138344B2 (enExample)
EP (1) EP1979359A1 (enExample)
JP (2) JP5416412B2 (enExample)
KR (1) KR101423343B1 (enExample)
CN (2) CN101374847A (enExample)
AU (1) AU2007209569B2 (enExample)
BR (1) BRPI0707330A2 (enExample)
CA (1) CA2637075A1 (enExample)
GB (1) GB0601406D0 (enExample)
RU (1) RU2448970C2 (enExample)
WO (1) WO2007085400A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0601406D0 (en) * 2006-01-24 2006-03-08 Novartis Ag Organic Compounds
JP6378192B2 (ja) * 2012-11-13 2018-08-22 エルジー エレクトロニクス インコーポレイティド データ送信方法及び装置、並びにデータ送信方法及び装置
WO2014145780A1 (en) 2013-03-15 2014-09-18 Biosensors International Group, Ltd. Purification of rapamycin derivatives
EP3109250A1 (en) * 2015-06-23 2016-12-28 Synbias Pharma AG Method for the synthesis of rapamycin derivatives
AR112834A1 (es) 2017-09-26 2019-12-18 Novartis Ag Derivados de rapamicina
PL3898637T3 (pl) 2018-12-18 2025-05-19 Novartis Ag Pochodne rapamycyny
CA3127448C (en) 2019-01-22 2024-06-04 Aeovian Pharmaceuticals, Inc. Mtorc modulators and uses thereof
WO2021195599A1 (en) * 2020-03-27 2021-09-30 Aeovian Pharmaceuticals, Inc. Mtorc1 modulators and uses thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5256790A (en) * 1992-08-13 1993-10-26 American Home Products Corporation 27-hydroxyrapamycin and derivatives thereof
GB9221220D0 (en) * 1992-10-09 1992-11-25 Sandoz Ag Organic componds
ATE228135T1 (de) * 1995-06-09 2002-12-15 Novartis Erfind Verwalt Gmbh Rapamycinderivate
AU2930501A (en) * 2000-01-07 2001-07-24 Transform Pharmaceuticals, Inc. High-throughput formation, identification, and analysis of diverse solid-forms
GB0601406D0 (en) * 2006-01-24 2006-03-08 Novartis Ag Organic Compounds

Similar Documents

Publication Publication Date Title
JP2013136631A5 (enExample)
JP2019524861A5 (enExample)
JP2010535722A5 (enExample)
EP4458348A3 (en) Pharmaceutical compositions containing substituted polycyclic pyridone derivatives and prodrug thereof
SI2906563T1 (en) Derivatives of pyrrolo (3,2-d) pyrimidine for the treatment of viral infections and other diseases
MY192109A (en) Aminopyrimidinyl compounds as jak inhibitors
RU2014149149A (ru) БИЦИКЛИЧЕСКИЕ СУЛЬФОНОВЫЕ СОЕДИНЕНИЯ ДЛЯ ИНГИБИРОВАНИЯ RORгамма АКТИВНОСТИ И ЛЕЧЕНИЯ ЗАБОЛЕВАНИЯ
JP2017508789A5 (enExample)
AR067413A1 (es) Compuestos heterociclicos que contienen ciclopenta[d]pirimidina inhibidores de proteinquinasas akt, composiciones farmaceuticas que los contienen, metodo de preparacion y uso de las mismas para el tratamiento de enfermedades hiperproliferativas, tales como cancer
JP2013503846A5 (enExample)
RU2017120970A (ru) Производные желчной кислоты в качестве агонистов fxr/tgr5 и способы их применения
EP4295841A3 (en) Sulfur (vi) fluoride compounds and their use in click-reaction
NZ599040A (en) 2,4-disubstituted pyrido[4,3-d]pyrimidin-5(6h)-one compounds for selective inhibitors of lrrk2 and syk kinases
RU2013151803A (ru) Бициклические гетероциклические соединения и их применения в терапии
AR082985A1 (es) INHIBIDORES DE PI3K-d Y METODOS DE SU USO Y PREPARACION
JP2015520140A5 (enExample)
PH12015501226A1 (en) Crystalline 6,7-unsaturated-7-carbamoyl morphinane derivative, and method for producing the same
AR085489A1 (es) Derivados de triazolopiridinas, composiciones farmaceuticas que los contienen, proceso para prepararlos, intermediarios de dicho proceso y uso de los mismos para el tratamiento de enfermedades autoinmunes e inflamatorias
AR080596A1 (es) Compuestos alquilamido y composiciones farmaceuticas
JP2017527590A5 (enExample)
RU2013126531A (ru) Селективные ингибиторы гликозидазы и их применение
MX373022B (es) Inhibidores de kv1.3 y su aplicacion medica.
RU2008134424A (ru) Способ получения производных рапамицина
PH12017501655B1 (en) Morphinan derivative
JP2015500842A5 (enExample)